Purchase this article with an account.
Guru Sharma; Evaluation of clinical response to treatment with FDA approved i-Lid Cleanser in patients with blepharitis in an optometric practice.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4448.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy, patient's compliance and tolerability of FDA approved i-Lid Cleanser in patients with mild to moderate blepharitis.
Patients with signs and symptoms of mild to moderate blepharitis were treated with FDA approved i-Lid Cleanser (NovaBay Pharmaceuticals, Inc.). A total of 18 patients with mild to moderate blepharitis were treated with i-Lid Cleanser twice daily for two weeks according to manufacturer's guidelines. Efficacy of the treatment was evaluated based on slit lamp examination pre- and post-treatment at 2 weeks. Following signs and symptoms were used to evaluate the severity of blepharitis and efficacy of treatment: eyelid redness, eyelid debris, eyelid swelling, eyelash collarettes and eyelid irritation. A scale of 0 to 3 (0-absent, 1-mild, 2-moderate, 3-severe) was used to identify and monitor blepharitis progression. Patient compliance, tolerability and ease of use was assessed based on patient feedback.
i-Lid Cleanser treatment showed improvement in subjective (discomfort, itching, dryness, eyelid irritation) and objective (redness, swelling, eyelash collarettes) symptoms of blepharitis. Patients with mild blepharitis reported good compliance (>95%) and ease of use of i-Lid Cleanser. Patients with mild blepharitis (n=10) showed significant improvement in their sign and symptoms. 100% of patients with mild blepharitis improved score by at least one point in all categories. Patients with moderate blepharitis (n=8) showed improvements at a slower rate and needed extended treatment period beyond 2 weeks to achieve similar improvements. The initial improvement ranged between one point to no point in individual categories. These patients had a lower compliance rate of about 80%. However, all patients reported ease of use and post-application comfort and relieve of symptoms.
Author believe the results are encouraging in group with mild blepharitis, i-Lid Cleanser treatment showed significant improvement in their signs and symptoms. However, patients with moderate blepharitis needed long-term treatment for similar effect. It may be prudent to study the efficacy of i-Lid Cleanser in more number of patients with both mild and moderate blepharitis to establish its beneficial effect in difficult to treat chronic blepharitis.
This PDF is available to Subscribers Only